(Q37082531)

18 August 2017

In-depth molecular profiling of the biphasic components of uterine carcinosarcomas (English)

1 reference

18 August 2017

Melissa K McConechy

1

1 reference

18 August 2017

Lien N Hoang

2

1 reference

18 August 2017

Michael Herman Chui

3

1 reference

18 August 2017

Janine Senz

4

1 reference

18 August 2017

Winnie Yang

5

1 reference

18 August 2017

Nirit Rozenberg

6

1 reference

18 August 2017

Robertson Mackenzie

7

1 reference

18 August 2017

Jessica N McAlpine

8

1 reference

18 August 2017

David G Huntsman

9

1 reference

18 August 2017

Blaise A Clarke

10

1 reference

18 August 2017

Cyril Blake Gilks

11

1 reference

18 August 2017

Cheng-Han Lee

12

1 reference

18 August 2017

9 April 2015

1 reference

The journal of pathology. Clinical research

18 August 2017

1 reference

18 August 2017

1

1 reference

18 August 2017

3

1 reference

18 August 2017

173-185

1 reference

Activation of PI3Kα by physiological effectors and by oncogenic mutations: structural and dynamic effects

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Molecular alterations of PIK3CA in uterine carcinosarcoma, clear cell, and serous tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

PI3K pathway dependencies in endometrioid endometrial cancer cell lines

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Integrated genomic characterization of endometrial carcinoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

MED12 alterations in both human benign and malignant uterine soft tissue tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Use of mutation profiles to refine the classification of endometrial carcinomas.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Structural effects of oncogenic PI3Kα mutations

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Carcinosarcomas (malignant mixed Müllerian tumor) of the uterus: advances in elucidation of biologic and clinical characteristics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Prognostic features of surgical stage I uterine carcinosarcoma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

The impact of multi-modal therapy on survival for uterine carcinosarcomas.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Uterine sarcomas: histogenesis and taxonomy

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4939881

Mesenchymal tumors of the uterus. 3. A clinical and pathologic study of 31 carcinosarcomas

3 September 2018

1 reference

7 January 2021

Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case

1 reference

7 January 2021

Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas

1 reference

7 January 2021

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin

1 reference

7 January 2021

Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms

1 reference

7 January 2021

Endometrioid carcinoma of the ovary with a prominent spindle-cell component, a source of diagnostic confusion. A report of 14 cases

1 reference

7 January 2021

Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27499902

12 December 2020

inferred from PubMed ID database lookup

Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27499902

12 December 2020

inferred from PubMed ID database lookup

Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27499902

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1002/CJP2.18

1 reference

18 August 2017

1 reference

18 August 2017

1 reference